S
Scott C. Harvey
Researcher at ACADIA Pharmaceuticals Inc.
Publications - 11
Citations - 825
Scott C. Harvey is an academic researcher from ACADIA Pharmaceuticals Inc.. The author has contributed to research in topics: Inverse agonist & Receptor. The author has an hindex of 9, co-authored 11 publications receiving 772 citations. Previous affiliations of Scott C. Harvey include University of Calgary.
Papers
More filters
Journal ArticleDOI
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.
D. M. Weiner,Herbert Y. Meltzer,Isaac Veinbergs,E. M. Donohue,Tracy A. Spalding,T. T. Smith,Nina Mohell,Scott C. Harvey,Jelveh Lameh,Norman Nash,Kimberly E. Vanover,Roger Olsson,Karuna Jayathilake,Myung A. Lee,Allan I. Levey,Uli Hacksell,Ethan S. Burstein,Robert E. Davis,Mark R. Brann +18 more
TL;DR: The muscarinic receptor agonist activities of NDMC are unique among antipsychotics, and provide a possible molecular basis for the superior clinical effects of clozapine pharmacotherapy.
Journal Article
5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics
D. M. Weiner,Ethan S. Burstein,Norman Nash,G. E. Croston,E. A. Currier,Kimberly E. Vanover,Scott C. Harvey,E. M. Donohue,H. C. Hansen,Carl-Magnus A. Andersson,Tracy A. Spalding,D. F. C. Gibson,Kirsten Krebs-Thomson,Susan B. Powell,Mark A. Geyer,Uli Hacksell,Mark R. Brann +16 more
TL;DR: Functional high-throughput screening of a diverse chemical library identified 530 ligands with inverse agonist activity at 5-HT2A receptors, including several series of compounds related to known antipsychotics, as well as a number of novel chemistries.
Journal ArticleDOI
Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist
Kimberly E. Vanover,David M. Weiner,Malath Makhay,Isaac Veinbergs,Luis R. Gardell,Jelveh Lameh,Andria L. Del Tredici,Fabrice Piu,Hans H. Schiffer,Thomas R. Ott,Ethan S. Burstein,Allan K. Uldam,Mikkel B. Thygesen,Nathalie Schlienger,Carl-Magnus A. Andersson,Thomas Son,Scott C. Harvey,Susan B. Powell,Mark A. Geyer,Bo-Ragner Tolf,Mark R. Brann,Robert E. Davis +21 more
TL;DR: ACP-103 is a potent, efficacious, orally active 5-HT2A receptor inverse agonist with a behavioral pharmacological profile consistent with utility as an antipsychotic agent and demonstrates >42.6% oral bioavailability in rats.
Journal ArticleDOI
The reinforcing properties of alcohol are mediated by GABA(A1) receptors in the ventral pallidum.
Harry L. June,Katrina L. Foster,Peter F. McKay,Regat Seyoum,James E. Woods,Scott C. Harvey,William J. A. Eiler,Collette Grey,Michelle R. Carroll,Shannan McCane,Cecily M. Jones,Wenyuan Yin,Dynesha Mason,Rancia Cummings,Marin Garcia,Chunrong Ma,P V V S Sarma,James M. Cook,Phil Skolnick +18 more
TL;DR: The present study indicates that βCCt is capable of antagonizing the reinforcing and the sedative properties of alcohol and may represent a prototype of a pharmacotherapeutic agent to effectively reduce alcohol drinking behavior in human alcoholics.
Journal ArticleDOI
Pharmacological Characterization of AC-90179 [2-(4-Methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist
Kimberly E. Vanover,Scott C. Harvey,Thomas Son,Stefania Risso Bradley,Henriette Kold,Malath Makhay,Isaac Veinbergs,Tracy Spalding,David M. Weiner,Carl-Magnus A. Andersson,Bo-Ragnar Tolf,Mark R. Brann,Uli Hacksell,Robert E. Davis +13 more
TL;DR: A compound with a similar pharmacological profile as AC-90179 and with increased oral bioavailability may have potential for the treatment of psychosis.